Used in targeted cancer therapies, particularly in the treatment of ovarian and other epithelial cancers. It binds specifically to the trophoblast glycoprotein (TPBG), which is overexpressed in certain tumor tissues, enabling selective delivery of therapeutic agents or facilitating immune-mediated destruction of cancer cells. This antibody serves as a reference standard in the development and validation of immunoassays and biosimilar products. It supports research in antibody-drug conjugates (ADCs) by providing a benchmark for binding affinity, specificity, and functional activity. Also utilized in pharmacokinetic and pharmacodynamic studies during preclinical and clinical stages of drug development.